BeOne Medicines AG
ONC
$316.99
-$5.38-1.67%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 5.30B | 4.95B | 4.54B | 4.16B | 3.79B |
| Total Other Revenue | 39.00M | 27.06M | 17.94M | 17.94M | 17.94M |
| Total Revenue | 5.34B | 4.97B | 4.56B | 4.18B | 3.81B |
| Cost of Revenue | 668.54M | 686.68M | 660.63M | 634.16M | 594.09M |
| Gross Profit | 4.67B | 4.29B | 3.90B | 3.54B | 3.22B |
| SG&A Expenses | 2.08B | 2.03B | 1.96B | 1.86B | 1.83B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.90B | 4.79B | 4.66B | 4.47B | 4.38B |
| Operating Income | 447.14M | 182.68M | -100.70M | -295.75M | -568.20M |
| Income Before Tax | 416.85M | 182.26M | -63.21M | -268.68M | -533.00M |
| Income Tax Expenses | 129.92M | 113.71M | 114.44M | 123.69M | 111.79M |
| Earnings from Continuing Operations | 286.93 | 68.55 | -177.64 | -392.37 | -644.79 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 286.93M | 68.55M | -177.64M | -392.37M | -644.79M |
| EBIT | 447.14M | 182.68M | -100.70M | -295.75M | -568.20M |
| EBITDA | 578.82M | 328.98M | 79.96M | -121.20M | -401.17M |
| EPS Basic | 34.01 | 7.62 | -22.00 | -48.27 | -79.74 |
| Normalized Basic EPS | 2.71 | 1.18 | -0.32 | -1.54 | -3.14 |
| EPS Diluted | 30.61 | 5.06 | -23.67 | -49.02 | -81.28 |
| Normalized Diluted EPS | 2.61 | 1.11 | -0.35 | -1.55 | -3.14 |
| Average Basic Shares Outstanding | 436.19M | 431.72M | 427.41M | 423.79M | 421.14M |
| Average Diluted Shares Outstanding | 34.89M | 34.19M | 33.53M | 32.93M | 32.39M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -8.16% | -3.69% | -2.25% |